论文部分内容阅读
[目的]探讨血清VEGF与VEGFR-2检测对评估直肠癌新辅助化疗疗效的临床价值。[方法]选择2013年7月~2014年7月医院收治的55例直肠癌患者作为研究组,患者采用奥沙利铂、亚叶酸钙和氟尿嘧啶组成的FOLFOX6方案,患者均完成2个疗程的治疗;另选择同期在医院体检的50例健康人群作为对照组,采用酶联免疫吸附试验检测两组血清VEGF、VEGFR-2水平表达水平。[结果]中分化、高分化组血清VEGF、VEGFR-2水平显著低于低分化组,高分化组血清VEGF、VEGFR-2水平又显著低于中分化组(P<0.05);Ⅳ期直肠癌患者血清VEGF、VEGFR-2水平显著高于Ⅲ期(P<0.05)。化疗前研究组血清VEGF、VEGFR-2水平均显著高于对照组,化疗后CR+PR组、SD组血清VEGF、VEGFR-2水平显著降低,PD组血清VEGF、VEGFR-2水平显著升高,化疗前后比较差异具有统计学意义(P<0.05);其中化疗后CR+PR组、SD组血清VEGF、VEGFR-2显著低于PD组,CR+PR组血清VEGF、VEGFR-2又显著低于SD组(P<0.05)。相关性分析显示研究组化疗前后血清VEGF、VEGFR-2表达均呈正相关关系(P<0.05)。[结论]VEGF、VEGFR-2是直肠癌发生、发展的敏感性生物学指标,通过检测患者血清VEGF、VEGFR-2水平能够有助于评价辅助化疗疗效及预后。
[Objective] To investigate the clinical value of serum VEGF and VEGFR-2 in assessing the efficacy of neoadjuvant chemotherapy for rectal cancer. [Methods] A total of 55 patients with rectal cancer admitted to the hospital from July 2013 to July 2014 were enrolled in the study. Patients were treated with oxaliplatin, leucovorin and fluorouracil FOLFOX6. All patients completed 2 courses of treatment In the same period, 50 healthy people in the hospital were selected as the control group. The levels of VEGF and VEGFR-2 were detected by enzyme-linked immunosorbent assay (ELISA). [Results] The serum levels of VEGF and VEGFR-2 in moderately differentiated and well-differentiated groups were significantly lower than those in poorly differentiated groups. The levels of VEGF and VEGFR-2 in well differentiated and differentiated groups were significantly lower than those in moderately differentiated and moderately differentiated groups (P <0.05) Serum levels of VEGF and VEGFR-2 were significantly higher than those in stage Ⅲ (P <0.05). Serum levels of VEGF and VEGFR-2 in pre-chemotherapy study group were significantly higher than those in control group. Serum levels of VEGF and VEGFR-2 in CR + PR group and SD group were significantly decreased after chemotherapy, and serum VEGF and VEGFR-2 levels in PD group were significantly increased The levels of VEGF and VEGFR-2 in CR + PR group and SD group were significantly lower than those in PD group after chemotherapy (P <0.05), while the levels of VEGF and VEGFR-2 in CR + PR group were significantly lower than those in PD group SD group (P <0.05). Correlation analysis showed that there was a positive correlation between serum VEGF and VEGFR-2 in the study group before and after chemotherapy (P <0.05). [Conclusion] The VEGF and VEGFR-2 are sensitive biological indicators of the occurrence and development of rectal cancer. The detection of serum VEGF and VEGFR-2 levels can be helpful to evaluate the efficacy and prognosis of adjuvant chemotherapy.